Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

09/02/2021 | 08:01am EDT

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at several upcoming investor conferences in September:

  • 2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday September 10, 2021 at 8:00 a.m. ET.
  • H.C. Wainwright 23rd Annual Global Investment Conference: Presentation will be available on-demand during the conference, starting on Monday, September 13, 2021 at 7:00 a.m. ET.
  • Baird’s 2021 Global Healthcare Conference: Presentation on Wednesday, September 15, 2021 at 12:15 p.m. ET. 
  • 2021 Cantor Fitzgerald Virtual Global Healthcare Conference: Presentation on Wednesday, September 29, 2021 at 4:00 p.m. ET.

A webcast of the presentations will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce obtained IND clearance for and exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com

Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com


Primary Logo


ę GlobeNewswire 2021
All news about JOUNCE THERAPEUTICS, INC.
10/07JOUNCE THERAPEUTICS : Initiates Enrollment of Phase 1 Trial Cohorts of JTX-8064
MT
10/07JOUNCE THERAPEUTICS : Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monother..
AQ
10/07Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monothe..
CI
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of Directors; ..
PU
09/15JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/15Jounce Therapeutics, Inc. Announces Board Changes
CI
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14JOUNCE THERAPEUTICS : Raymond James Upgrades Jounce Therapeutics to Outperform From Market..
MT
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
More news
Analyst Recommendations on JOUNCE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 45,7 M - -
Net income 2021 -69,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,04x
Yield 2021 -
Capitalization 436 M 436 M -
Capi. / Sales 2021 9,55x
Capi. / Sales 2022 22,7x
Nbr of Employees 128
Free-Float 81,7%
Chart JOUNCE THERAPEUTICS, INC.
Duration : Period :
Jounce Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOUNCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 8,51 $
Average target price 14,50 $
Spread / Average Target 70,4%
EPS Revisions
Managers and Directors
Richard Murray President, Chief Executive Officer & Director
Kimberlee Cobleigh Drapkin Chief Financial Officer & Treasurer
Perry A. Karsen Chairman
Elizabeth G. Trehu Chief Medical Officer
Stephen Farrand Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOUNCE THERAPEUTICS, INC.21.57%436
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156